RECRUITING

Cardiac Radioablation for VT

Talk to us

Conditions

Ventricular TachycardiaMyocardial Infarction

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this interventional study is to determine the minimum dose necessary for successful cardiac radioablation of refractory ventricular tachycardia (VT) and to study the utility of target volume definition using Delayed Enhancement Cardiac MRI (DE-CMR) .

Official Title

A Phase I/II Study of Cardiac Radioablation for Refractory Ventricular Tachycardia

Quick Facts

Study Start:2025-02
Study Completion:2026-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06593418

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must be 18 years or older.
  2. * Automatic implanted cardiac defibrillator present.
  3. * VT is monomorphic with at least two episodes of VT within an eight week (56 day) period as recorded by an AICD or heart failure related to VT or VT storm.
  4. * Ejection fraction ≥20%.
  5. * At least one previous cardiac ablation for VT.
  6. * VT refractory despite antiarrhythmic medications.
  7. * Likely to live for 12 months in the absence of VT.
  8. * AICD in a position in the chest RT to be given without direct radiation.
  9. * Woman of reproductive age must ensure that she won't become pregnant or breastfeed at the time of RT.
  10. * The participant has no contraindications to a Cardiac MRI as per routine Cardiology practice.
  1. * Class IV heart failure
  2. * Abandoned leads.
  3. * Prior radiation therapy to the chest or upper abdomen.
  4. * Interstitial lung disease.

Contacts and Locations

Study Contact

John Roberston, MD
CONTACT
248-551-7038
john.robertson@corewellhealth.org
Mary Martin, RN
CONTACT
248-551-0439
mary.martin@corewellhealth.org

Principal Investigator

John Robertson, MD
PRINCIPAL_INVESTIGATOR
Corewell Health William Beaumont University Hospital

Study Locations (Sites)

Corewell Health William Beaumont University Hospital
Royal Oak, Michigan, 48073
United States

Collaborators and Investigators

Sponsor: William Beaumont Hospitals

  • John Robertson, MD, PRINCIPAL_INVESTIGATOR, Corewell Health William Beaumont University Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02
Study Completion Date2026-08

Study Record Updates

Study Start Date2025-02
Study Completion Date2026-08

Terms related to this study

Additional Relevant MeSH Terms

  • Ventricular Tachycardia
  • Myocardial Infarction